Last week we had the pleasure of attending the EHA 2022 hybrid congress and the GenoMed4All’s SCD team took the conference by storm! Here’s a sneak peek at the work our colleagues presented, together with the conference proceedings if you wish to go for a deep-dive:
- Rafaella Colombatti (Università di Padova) gave an oral presentation on our results regarding radiomics and AI for Sickle Cell Disease.
- Our colleague Sigrid van der Veen (UMC Utrecht) showcased the strong collaboration between ERN-EuroBloodNet’s clinical members during EHA’s poster session.
The use of Artificial Intelligence (AI) for personalized medicine has recently guided improvements in the diagnostic pathway of many diseases. The EU Project GENOMED4ALL: “Genomics and personalized Medicine for All through Artificial Intelligence in Haematological Diseases” aims at using European data of patients affected by Sickle Cell Disease (SCD) to find correlation between -omics data – and phenotype, seizing the opportunity to improve diagnostics through AI.
Sickle cell disease (SCD) is a hereditary and chronic life-threatening disorder, characterized by haemolytic anaemia. Increased 2,3-diphosphoglycerate (2,3-DPG) concentrations, along with decreased oxygen affinity of hemoglobin, may be related to the variability of clinical outcomes in SCD. Furthermore, genomic health data holds promise to improve the prediction of disease severity in SCD. Based on the integration of genomics, metabolomics and clinical data from 1000 SCD patients, to be included in 2022, GenoMED4all aims to develop Artificial Intelligence (AI) based deep learning algorithms to improve the prediction of disease severity and phenotype in SCD.
